MTOR and cardiac rhabdomyoma: Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been documented on various case studies to be effective and safe in treating patients with cardiac rhabdomyoma, particularly in tumors which are not resectable [77].